Dig Liver Dis
Among those who no longer took the GLP-1, 82 percent who lost weight regained 25 percent or more of their initial weight loss within a year of stopping the drug
Potential Causes of Allodynia Allodynia is associated with several neurological and metabolic conditions, including: Peripheral Neuropathy (due to diabetes, chemotherapy, or autoimmune disorders) Fibromyalgia (central pain sensitisation disorder) Migraine Disorders (involving trigeminal nerve hypersensitivity) Neuroinflammation and Immune Dysregulation (as seen in post-viral syndromes) Medication Side Effects, including possible links to GLP-1 receptor agonists Mechanisms: How GLP-1 Medications May Contribute to Allodynia GLP-1 receptor agonists (e.g., Mounjaro, Wegovy) are widely used for weight loss and glycemic control due to their role in glucose-dependent insulin secretion and appetite suppression
Common Drugs : Semaglutide, Liraglutide, Dulaglutide, and Tirzepatide (dual GIP/GLP-1 agonist)
Treatment decisions should be made in consultation with a qualified healthcare professional
Tirzepatide activating both receptors simultaneously is why clinical trials show it outperforming semaglutide on average weight lost though both are clinically remarkable medications
